LPCN 1144

Lipocine Inc. · Phase 2 active Small molecule

At a glance

Generic name	LPCN 1144
Also known as	testosterone undecanoate
Sponsor	Lipocine Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial (PHASE2)
The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LPCN 1144 CI brief — competitive landscape report
LPCN 1144 updates RSS · CI watch RSS
Lipocine Inc. portfolio CI